Ovarian cancer trials in United Kingdom

In United Kingdom 64 Also abroad 795

64 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Where
London
Age
18 years and over
People
156 worldwide
Run by
Context Therapeutics Inc.
See details and how to joinNCT06515613 · EU 2025-523968-20-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Where
Birmingham, Cambridge, Edinburgh, Leicester, Liverpool, London, Preston, Sutton
Age
18 years and over
People
770 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06824467 · EU 2023-508015-23-00
Phase 1/2Taking people
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003).
Where
Brighton, Fulham, London, Manchester, Sutton
Age
18 years and over
People
605 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06843447 · EU 2024-514674-47-00
Phase 3Taking people
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Where
Bath, Cambridge, Leicester, London, Manchester
Age
18 years and over
People
900 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07318558 · EU 2023-508047-40-00
Phase 1Taking people
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Where
Cambridge, Edinburgh, Glasgow, Leeds, Leicester, London, Preston, Sutton
Age
18 years and over
People
50
Run by
Epitopea Ltd
See details and how to joinNCT07665515
Phase 1Not yet taking people in United Kingdom
A Study of LY4336619 in Adult Participants With Advanced Solid Tumors
Where
Manchester, Sutton
Age
18 years and over
People
370 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07928258 · EU 2026-526553-33-00
Phase 3Taking people
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Where
Cambridge
Age
18 years and over
People
950 worldwide
Run by
AstraZeneca
See details and how to joinNCT07851025 · EU 2026-526895-22-00
Phase 3Taking people
A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)
Where
Lancaster
Age
18 years and over
People
802 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07776691 · EU 2025-524592-22-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
London, Manchester
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Where
Bath, Leeds, London, Manchester, Torquay
Age
18 years and over
People
1,630 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07213804 · EU 2025-522255-25-00
Phase 1/2Taking people
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Where
London
Age
18 years and over
People
334 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06303505 · EU 2024-511074-80-01
Phase 3Taking people
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Where
Cambridge, Edinburgh, Glasgow, Leicester, London, Manchester, Sutton
Age
18 years and over
People
270 worldwide
Run by
Verastem, Inc.
See details and how to joinNCT06072781 · EU 2023-508204-38-00
No phaseTaking people
MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women With Complex Pelvic Adnexal Masses ≤ 8cm.
Where
Guildford
Age
18 years to 100 years
People
25
Run by
Royal Surrey County Hospital NHS Foundation Trust
See details and how to joinNCT06638593
Phase 1Taking people
A Study of MGC026 in Participants With Advanced Solid Tumors
Where
Oxford, Sutton
Age
18 years and over
People
394 worldwide
Run by
MacroGenics
See details and how to joinNCT06242470
Phase 3Taking people
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Where
Cambridge, London, Manchester, Oxford, Sheffield
Age
18 years and over
People
582 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06819007 · EU 2024-516982-35-00
Phase 2/3Taking people
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Where
Bath, Glasgow, Headington, London, Northampton
Age
18 years and over
People
860 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06161025 · EU 2023-507914-28-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Cambridge, Coventry, London, Nottingham
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Where
Glasgow, London, Manchester
Age
18 years and over
People
542 worldwide
Run by
Artios Pharma Ltd
See details and how to joinNCT04657068
Phase 1/2Taking people
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Where
Leeds, London, Manchester, Newcastle upon Tyne, Sutton
Age
18 years and over
People
245 worldwide
Run by
BioNTech SE
See details and how to joinNCT07186842 · EU 2025-522613-26-00
Phase 3Taking people
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Where
Cambridge, Cardiff, Guildford, Leeds, Liverpool, London, Manchester Greater, Northampton, Northwood, Sutton, Taunton
Age
18 years and over
People
466 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07214779 · EU 2025-522748-42-00
Phase 3Taking people
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
Where
London
Age
18 years and over
People
450 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07286266 · EU 2025-523361-25-00
Phase 1/2Taking people
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Where
Cambridge, Cardiff, London
Age
18 years and over
People
460 worldwide
Run by
AstraZeneca
See details and how to joinNCT05123482 · EU 2022-502759-70-01
Phase 1Taking people
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Where
Manchester
Age
15 years and over
People
282 worldwide
Run by
Xencor, Inc.
See details and how to joinNCT06276491
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Glasgow, Scotland, London, Newcastle upon Tyne
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 1/2Taking people
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Where
Cambridge, Glasgow, Scotland, London, Sutton
Age
18 years to 130 years
People
622 worldwide
Run by
AstraZeneca
See details and how to joinNCT05797168 · EU 2022-502576-23-00